CGMs are wearables that help measure blood sugar and can be used with insulin pumps. Dexcom, a CGM manufacturer based in San Diego, said it analyzed Optum insurance claims and found CGM use doubled among patients with insulin regimens after they began taking a GLP-1 drug. For patients that use basal insulin or non-insulin therapies, CGM use nearly quadrupled after taking GLP-1s.
Dexcom said its findings are in contrast to industry concerns that GLP-1 drugs may lead to less usage of diabetes monitoring products.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
